Evan Seigerman, an analyst from BMO Capital, maintained the Buy rating on Regeneron (REGN – Research Report). The associated price target was lowered to $903.00.
Evan Seigerman has given his Buy rating due to a combination of factors that highlight Regeneron’s potential for growth despite current challenges. The recent court decision regarding the Eylea biosimilar case against Amgen is seen as a modest setback, but it does not overshadow the long-term prospects of the company. The market has already adjusted to the pressures on Eylea, and Seigerman sees a favorable setup for Regeneron as it heads into a catalyst-rich 2025.
Seigerman is optimistic about Regeneron’s broader pipeline, particularly in oncology and other areas. The upcoming data releases for itepekimab in COPD, fianlimab in NSCLC/melanoma, and Phase 2 COURAGE data are expected to drive growth. Furthermore, Regeneron’s track record of effectively converting R&D investments into enterprise value growth is a strong indicator of its potential for sustained success in the biotech sector.
In another report released on March 6, TD Cowen also maintained a Buy rating on the stock with a $970.00 price target.